AI could spare bowel cancer patients from unneeded treatment
An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.
Newsletters and Deep Dive digital magazine
An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.
AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.
Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.
Editor's Picks
Newsletters and Deep Dive
digital magazine